Meanwhile, TACE increases tumor hypoxia, leading to the upregulation of hypoxia-inducible factor-1α, which upregulates the expression of vascular endothelial growth factor and platelet-derived growth factor and increases tumor angiogenesis, suggesting the combination of TACE and targeted therapy (27). The gene discussed is VEGFA; the disease is neoplasm.